Log In
Print
BCIQ
Print
Print this Print this
 

cyclic pyranopterin monophosphate (cPMP) replacement therapy (ALXN1101)

  Manage Alerts
Collapse Summary General Information
Company Alexion Pharmaceuticals Inc.
DescriptionIntravenous Escherichia coli-derived cyclic pyranopterin monophosphate (cPMP)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard Indication Neurology (unspecified)
Indication DetailsTreat molybdenum cofactor deficiency (MoCD) type A
Regulatory Designation U.S. - Breakthrough Therapy (Treat molybdenum cofactor deficiency (MoCD) type A)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$3.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today